Fluticasone Furoate In The Treatment Of Copd

Patent No. EP3148521 (titled "Fluticasone Furoate In The Treatment Of Copd") was filed by Glaxosmithkline on May 27, 2015. The application was issued on Dec 18, 2019.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GILL JENNINGS & EVERYSep 16, 2020GILL JENNINGS & EVERY
TEVA PHARMACEUTICALSSep 8, 2020ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3148521

GLAXOSMITHKLINE
Application Number
EP15726106A
Filing Date
May 27, 2015
Status
Revoked
May 19, 2025
Publication Date
Dec 18, 2019